Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management of patients with partially platinum-sensitive relapse [6–12 months platinum-free interval (PFI)] is uncl...

Descripción completa

Detalles Bibliográficos
Autores principales: Poveda, A., Vergote, I., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Kaye, S. B., Colombo, N., Lebedinsky, C., Parekh, T., Gómez, J., Park, Y. C., Alfaro, V., Monk, B. J.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003616/
https://www.ncbi.nlm.nih.gov/pubmed/20643862
http://dx.doi.org/10.1093/annonc/mdq352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003616/
https://www.ncbi.nlm.nih.gov/pubmed/20643862
http://dx.doi.org/10.1093/annonc/mdq352

Ejemplares similares